Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?

Niki Katsiki, Ele Ferrannini

First Department of Internal Medicine, Diabetes Center, Division of Endocrinology and Metabolism, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece
C.N.R. Institute of Clinical Physiology, Pisa, Italy

ARTICLE INFO

Article history:
Received 10 June 2020
Received in revised form 21 August 2020
Accepted 21 August 2020
Available online 26 August 2020

Keywords:
Metformin
Pioglitazone
Dipeptidyl peptidase-4 inhibitors
Glucagon-like peptide-1 receptor agonists
Sodium-glucose co-transporter-2 inhibitors
C-reactive protein
Interleukin 6
Ferritin

ABSTRACT

Inflammation is implicated in the development and severity of the coronavirus disease 2019 (COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when uncontrolled, is also recognized as an important risk factor for COVID-19 morbidity and mortality. Furthermore, certain inflammatory markers (i.e. C-reactive protein (CRP), interleukin-6 (IL-6) and ferritin) were reported as strong predictors of worse outcomes in COVID-19 positive patients. The same biomarkers have been associated with poor glycemic control. Therefore, achieving euglycemia in patients with diabetes is even more important in the era of the COVID-19 pandemic. Based on the above, it is clinically interesting to elucidate whether antidiabetic drugs may reduce inflammation, thus possibly minimizing the risk for COVID-19 development and severity. The present narrative review discusses the potential anti-inflammatory properties of certain antidiabetic drugs (i.e. metformin, pioglitazone, sitagliptin, linagliptin, vildagliptin, alogliptin, saxagliptin, liraglutide, dulaglutide, exenatide, lixisenatide, semaglutide, empagliflozin, dapagliflozin, canagliflozin), with a focus on CRP, IL-6 and ferritin.

© 2020 Elsevier Inc. All rights reserved.

Contents

1. Introduction .................................................................................................................................................. 2
   1.1. Metformin ........................................................................................................................................... 2
   1.2. Pioglitazone ......................................................................................................................................... 2
   1.3. Dipeptidyl peptidase-4 inhibitors (DPP4-i) ....................................................................................... 2
   1.4. Sitagliptin ............................................................................................................................................ 2
      1.4.1. Linagliptin .................................................................................................................................... 3
      1.4.2. Vildagliptin ................................................................................................................................ 3
      1.4.3. Alogliptin ................................................................................................................................... 3
      1.4.4. Saxagliptin .................................................................................................................................. 3
   1.5. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ..................................................................... 3
      1.5.1. Liraglutide .................................................................................................................................... 3
      1.5.2. Dulaglutide .................................................................................................................................. 3
      1.5.3. Exenatide ....................................................................................................................................... 3
      1.5.4. Lixisenatide ................................................................................................................................... 3
      1.5.5. Semaglutide ................................................................................................................................. 4
   1.6. Sodium Glucose Co-Transporter-2 inhibitors (SGLT2i) ................................................................. 4
      1.6.1. Empagliflozin .............................................................................................................................. 4
      1.6.2. Dapagliflozin ............................................................................................................................. 4
      1.6.3. Canagliflozin ............................................................................................................................. 4
   1.7. Limitations of current evidence ........................................................................................................ 4

2. Conclusions .................................................................................................................................................. 5

Declaration of competing interest ................................................................................................................ 5

References ....................................................................................................................................................... 5

* Corresponding author at: C.N.R. Institute of Clinical Physiology, Via Savi 10, 56126 Pisa, Italy.
E-mail address: ferranni@ifc.cnr.it (E. Ferrannini).
1. Introduction

Inflammation plays a key role in the development and severity of the new coronavirus disease 2019 (COVID-19).Indeed, severe COVID-19 pneumonia is related to systemic hyper-inflammation (or cytokine storm). Serum C-reactive protein (CRP), interleukin-6 (IL-6) and ferritin have been recognized as strong predictors of the COVID-19 severity and mortality. Diabetes is also considered as a significant risk factor for COVID-19 morbidity and mortality. Indeed, a recent meta-analysis (83 studies, n = 78,874 hospitalized patients with confirmed COVID-19) reported that pre-existing diabetes almost doubled the risk for severe/critical COVID-19 (n = 22 studies; odds ratio (OR) 2.10, 95% confidence interval [95%CI] 1.71–2.57) and almost tripled in-hospital mortality (OR 2.68, 95%CI 2.09–3.44). Similar results were reported in another meta-analysis (33 studies, n = 16,003 patients) for both COVID-19 severity (OR 2.75, 95%CI 2.09–3.62) and mortality (OR 1.90, 95%CI 1.37–2.64). Furthermore, chronic, low-grade inflammation is associated with insulin resistance and hyperglycemia, and inflammatory markers, such as CRP, IL-6 and ferritin, have been quantitatively related to HbA1c. This highlights the importance of achieving euglycemia in patients with diabetes, especially in the era of COVID-19.

Based on the above, it is relevant to establish whether antidiabetic therapies may reduce the inflammatory reaction, thus possibly minimizing the risk for COVID-19 development and severity. The present narrative review discusses the potential anti-inflammatory properties of certain antidiabetic drugs (i.e. metformin, pioglitazone, sitagliptin, liraglutide, albiglutide, saxagliptin, lixisenatide, exenatide, semaglutide, dapagliflozin, canagliflozin), based mainly on available data from clinical studies and with a focus on CRP, IL-6 and ferritin.

1.1. Metformin

Metformin mechanism of action classically involves both AMP-activated protein kinase (AMPK)-independent and AMPK-dependent pathways. In many studies, this drug has been shown to inhibit mitochondrial respiration as well as mitochondrial glycerophosphate dehydrogenase, leading to suppression of ATP production and hepatic gluconeogenesis, whereas AMPK activation enhances catabolic pathways. Metformin mechanism of action classically involves both AMPK and inflammatory properties of certain antidiabetic drugs (i.e. metformin, pioglitazone, sitagliptin, liraglutide, albiglutide, saxagliptin, lixisenatide, exenatide, lixisenatide, semaglutide, empagliflozin, dapagliflozin, canagliflozin), based mainly on available data from clinical studies and with a focus on CRP, IL-6 and ferritin.

1.2. Pioglitazone

Pioglitazone is a peroxisome proliferator-activated receptor (PPAR)-γ agonist that reduces insulin resistance by stimulating lipogenesis and suppressing lipolysis in the adipose tissue, as well as by decreasing hepatic triglycerides, visceral fat mass and activity, thus promoting peripheral insulin sensitivity. Furthermore, pioglitazone enhances glucose uptake by the skeletal muscle and beta-cell function.

In animal studies, the expression of IL-6 was suppressed in human monocyes as well as in white adipose tissue and cardiomyocytes. In 34 T2DM patients, pioglitazone therapy for 6 months significantly decreased circulating CRP levels (from 1.73 ± 1.30 to 1.23 ± 0.75 μg/mL, p < 0.05); IL-6 levels were non-significantly reduced (from 1.50 ± 0.57 μg/mL, p = ns). Similarly, a previous meta-analysis reported that pioglitazone significantly lowered hsCRP levels (15 trials, n = 1448 T2DM patients; SMD = −0.54, 95%CI: −0.92 to −0.16, p < 0.05; I² = 90%) but not IL-6 (4 trials, n = 422 T2DM patients; SMD = −1.5, 95%CI: −3.08 to 0.07, p = 0.06). No data exist on the impact of pioglitazone on ferritin.

1.3. Dipeptidyl peptidase-4 inhibitors (DPP4-i)

DPP4-i increase the endogenous levels of bioactive incretins, including glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), by inhibiting their enzymatic degradation. As a consequence, insulin secretion is enhanced in a glucose-dependent way, whereas glucagon secretion is suppressed.

DPP4-i may exert immune regulatory functions, that are potentially beneficial in autoimmune and inflammatory diseases, as recently reviewed. A recent meta-analysis (n = 1607 T2DM patients; 16 trials) reported a significant reduction in CRP levels following DPP4-i therapy compared with placebo (WMD: −0.86 μg/mL; 95%CI: −1.36 to −0.36, p = 0.001; I² = 84.4%).

1.4. Sitagliptin

Sitagliptin (either 50 or 100 mg/day) has been reported to significantly decrease CRP levels in 67 newly diagnosed T2DM patients at 12 weeks (from 6.1 ± 1.0 to 3.3 ± 0.5 μg/mL, p < 0.05) in 48 patients at 3 months (from 0.8 ± 0.1 to 0.5 ± 0.1 μg/mL, p < 0.05) in 22 patients at 12 weeks (by 24%, p < 0.05) in 36 patients at 6 weeks (by 44.9%, p = 0.006) and in 20 T2DM patients at 6 months [from 1.60 (0.45–2.85) to 0.70 (0.35–1.25) μg/mL, p < 0.01]. Furthermore, hsCRP was significantly reduced over 7 years of follow-up in T2DM patients treated with sitagliptin (100 mg/day) in combination with either metformin (n = 201; from 2.4 ± 0.9 to 1.8 ± 0.4 μg/mL, p < 0.05), pioglitazone (n = 196; from 2.5 ± 1.0 to 2.0 ± 0.6, p < 0.05) or sulfonylureas (n = 194; from 2.3 ± 0.8 to 1.8 ± 0.3 μg/mL, p < 0.05). Sitagliptin (100 mg/day)-induced CRP decrease was also reported elsewhere. In contrast, the Sitagliptin Investigation on Glycemic Effects in Yokohama (SINGLE-Y) study, involving 270 T2DM patients, found that 3 months of sitagliptin (50 mg/day) did not affect hsCRP (from 0.12 ± 0.78 to 0.09 ± 0.10 μg/mL, p = ns). Furthermore, no significant change in hsCRP was observed in another study of 205 T2DM patients treated with sitagliptin (25, 50, or 100 mg/day) for 12 months. Similar results were reported in other studies using sitagliptin 50 or 100 mg/day.

IL-6 levels were non-significantly decreased at 3 months in 24 sitagliptin-treated T2DM patients (from 3.5 ± 0.6 to 2.7 ± 0.3 μg/mL, reduced in a duration- and dose-dependent manner (i.e., at a dose of 1000 mg q.d. for 1 year) after 12 months of metformin therapy in T2DM patients (n = 112). Similarly, metformin (titrated up to 1500 mg q.d.) significantly lowered IL-6 (from 133 ± 68 to 114 ± 57 pg/mL, p < 0.05) at 12 months in 36 T2DM patients. In the same study, ferritin was also decreased (from 171 ± 23 to 164 ± 19 ng/mL, p < 0.05) following metformin treatment.
p = ns),\textsuperscript{41} whereas they were significantly lowered by sitagliptin in 22 T2DM patients at 12 weeks (by 24%, p < 0.05),\textsuperscript{42} as well as at 12 months (from 15.8 ± 6.2 to 12.8 ± 4.3 pg/mL, p = 0.03) in 31 T2DM patients.\textsuperscript{53}

The impact of sitagliptin on ferritin has not been investigated. There is only one study involving 5 T2DM patients with major beta-thalassemia treated with sitagliptin; there was a trend of ferritin reduction in 4/5 patients.\textsuperscript{54}

\subsection*{1.4.1. Linagliptin}

Data on linagliptin and CRP are scarce. In one study, involving 21 T2DM patients on hemodialysis (HD), no change in CRP levels was found at 6 months after initiating linagliptin.\textsuperscript{55} Similar results were reported among 35 T2DM patients undergoing HD receiving linagliptin for 3 months\textsuperscript{56} and among 45 T2DM patients on linagliptin for 26 weeks.\textsuperscript{57} Linagliptin was found to inhibit IL-6 production in human umbilical vein endothelial cells\textsuperscript{58} and monocytes.\textsuperscript{59} No relevant human studies are available. There is only one study investigating ferritin changes after 6 months of linagliptin therapy among 25 T2DM patients on HD, reporting no effect.\textsuperscript{60}

\subsection*{1.4.2. Vildagliptin}

Among 60 T2DM patients with coronary artery disease (CAD), 12-week vildagliptin therapy reduced hsCRP by 60%.\textsuperscript{61} Similar effects were also reported in other studies.\textsuperscript{62–66} Neutral studies also exist.\textsuperscript{67,68}

In animal studies, vildagliptin was shown to attenuate the isoproterenol-induced increased mRNA expression of IL-6 in cardiomyocytes.\textsuperscript{69} However, no change in IL-6 was observed following 12 weeks of vildagliptin therapy in 27 T2DM patients.\textsuperscript{70} In contrast, an- other study found a significant decrease in IL-6 levels in vildagliptin-treated T2DM patients at 12 weeks (from 2.47 ± 0.52 to 1.54 ± 0.16 pg/mL, p < 0.01).\textsuperscript{71} No study has investigated the impact of vildagliptin on ferritin.

\subsection*{1.4.3. Alogliptin}

Limited data exist on the effects of alogliptin on CRP or IL-6. No significant change in hsCRP levels were observed at 24 months following alogliptin treatment in the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) (n = 172 T2DM patients).\textsuperscript{72} In animal models, alogliptin decreased IL-6,\textsuperscript{73,74} as also shown in \textit{in vitro} studies.\textsuperscript{75} In humans, in the SPEAD-A study, IL-6 was significantly increased [baseline = 2.1 (1.4, 2.7) ng/dL; median change 0.1 (−0.3, 0.7), p < 0.05] in alogliptin-treated T2DM patients followed for 24 months.\textsuperscript{72} There are no data on ferritin and alogliptin.

\subsection*{1.4.4. Saxagliptin}

In diabetic mice, saxagliptin was able to reduce serum CRP.\textsuperscript{76} However, no impact on hsCRP was observed in saxagliptin-treated T2DM patients compared with placebo in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial.\textsuperscript{77} Similarly, saxagliptin did not affect the secretion of IL-6 from adipocytes in 40 non-diabetic overweight/obese patients followed for 6 weeks.\textsuperscript{78} No data on ferritin and saxagliptin exist.

\subsection*{1.5. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)}

GLP-1 RAs promote insulin secretion by the beta-cells and inhibit glucagon secretion by the alpha-cells of the pancreas.\textsuperscript{79} GLP-1 RAs also delay gastric emptying and suppress food intake.\textsuperscript{79} GLP-1 RAs have been reported to exert anti-inflammatory properties \textit{via} several molecular mechanisms, both \textit{in vivo} and \textit{in vitro}.\textsuperscript{80}

\subsection*{1.5.1. Liraglutide}

Liraglutide has been reported to exert antioxidant and anti-inflammatory effects in \textit{vivo}\textsuperscript{81,82} as well as in T2DM patients\textsuperscript{83} and in patients with non-ST-segment elevation myocardial infarction.\textsuperscript{84} In this context, among 52 T2DM patients receiving liraglutide at a dose of 0.6–1.2 mg/day for 12 weeks, CRP was significantly decreased (by 0.89 ± 0.59 mg/L, p = 0.018).\textsuperscript{85} Similar results were observed following liraglutide (1.2–1.8 mg/day) therapy for 24 weeks in T2DM patients.\textsuperscript{86–88} Of note, liraglutide-induced weight loss was related to improvements in circulating hsCRP levels in obese patients with prediabetes or T2DM.\textsuperscript{89} In contrast, no significant changes in hsCRP were observed among 44 T2DM patients after 6 and 12 weeks of liraglutide (1.2 and 1.8 mg/day, respectively)\textsuperscript{90} as well as among 165 T2DM after 14 weeks of liraglutide (0.65–1.9 mg/day).\textsuperscript{92}

Liraglutide significantly reduced both circulating and hepatic levels of IL-6 in diabetic mice\textsuperscript{93} as well as IL-6 expression in the hippocampus, suggesting protection against neuroinflammation.\textsuperscript{84} In T2DM patients, a recent meta-analysis of 13 randomized controlled trials (n = 1187; follow-up ranged from 8 to 24 weeks), found that IL-6 concentrations were significantly lower [mean difference (MD): −3.90; 95%CI: −5.03 to −2.76, p < 0.00001] in the liraglutide group (1.2 mg/day) compared with the controls in those with stage 3 diabetic nephropathy.\textsuperscript{95} Similarly, liraglutide (1.2–1.8 mg/day) for 26 weeks led to a significant reduction in circulating IL-6 levels (−22.6%; 95%CI: −38.1, −3.2, p = 0.025) among 19 type 1 DM patients.\textsuperscript{96} One study, however, reported no changes in IL-6 concentrations after 14 weeks of liraglutide (0.65–1.9 mg/day).\textsuperscript{92}

Liraglutide (0.9 mg/day for 24 weeks) was shown to significantly decrease serum ferritin levels (from 158.9 ± 147.4 to 91.8 ± 69.9 ng/mL, p < 0.01) in 19 T2DM patients with NASH/LI and liver biopsy in the LEAN-J study.\textsuperscript{91} No other relevant data exist.

\subsection*{1.5.2. Dulaglutide}

There are limited data on dulaglutide, CRP and IL-6. In one study, 755 T2DM patients were randomized to receive either dulaglutide once weekly (0.75 or 1.5 mg) or placebo; changes from baseline in hsCRP levels at 16 weeks were −0.98, −0.08 and 0.62 mg/L for dulaglutide 1.5 mg (p < 0.001 compared with placebo), dulaglutide 0.75 mg, and placebo, respectively.\textsuperscript{98} In another smaller study, once weekly dulaglutide (0.75 mg in 8 T2DM patients and 1.5 mg in 5 patients) led to a significant reduction in serum IL-6 levels (from 1.42 ± 0.84 to 0.31 ± 0.23 pg/mL, p < 0.001) at 26 weeks.\textsuperscript{99} No study investigated the effects of dulaglutide on ferritin.

\subsection*{1.5.3. Exenatide}

Exenatide reduced circulating markers of oxidative stress and inflammation in T2DM patients.\textsuperscript{100,101} In 61 T2DM patients on exenatide (5 or 10 μg twice daily) for a mean of 1.4 years, circulating CRP levels decreased from 5.1 ± 1.7 to 2.7 ± 1.2 mg/L (p < 0.001).\textsuperscript{102} Similarly, serum hsCRP was lowered by 34% (p = 0.05) in 38 T2DM patients taking exenatide (5 μg twice per day) for a mean of 26 weeks.\textsuperscript{103} In another study involving 23 T2DM patients (11 patients on placebo and 12 patients on exenatide 5 μg twice daily for 4 weeks, followed by 10 μg twice daily for 12 weeks), hsCRP was significantly reduced in the exenatide group (−37%) compared with placebo (+137%).\textsuperscript{104} Exenatide therapy for 1 year also led to lower hsCRP levels (from 1.81 ± 0.25 to 1.30 ± 0.22 mg/L, p = 0.008) in 30 T2DM patients.\textsuperscript{104}

Circulating IL-6 levels fell from 3.01 ± 0.49 to 2.07 ± 0.57 pg/mL (p < 0.05) after 12 weeks of exenatide treatment (10 μg twice daily) in 12 T2DM patients.\textsuperscript{105} In another study, 18 T2DM patients received exenatide for 3 months (5 μg twice daily for the first month, followed by 10 μg for the next 2 months); serum IL-6 concentrations were reduced from 15.69 ± 10.86 ng/mL at baseline to 10.76 ± 5.15 ng/mL at 3 months (p = 0.001).\textsuperscript{106} No data on the effects of exenatide on ferritin are currently available.

\subsection*{1.5.4. Lixisenatide}

Lixisenatide was reported to downregulate the expression of proinflammatory cytokines, including IL-6, in human fibroblast-like
synoviocytes and in primary chondrocytes.\textsuperscript{107,108} No human study evaluated the impact of lixisenatide on CRP, IL-6 and ferritin.

1.5.5. Semaglutide

In a 52-week weight management trial (n = 957 non-diabetic obese patients randomized to oral semaglutide 0.05–0.4 mg/day or placebo), hsCRP was reduced by up to 43\% vs placebo in all semaglutide groups at week 52; these reductions were either significant or close to significance.\textsuperscript{109} However, statistical significance was lost after adjustment for change in body weight.\textsuperscript{109} In another 52-week randomized, open-label trial involving 412 T2DM patients on oral semaglutide 14 mg and 410 T2DM patients on empagliflozin 25 mg, greater decreases in CRP levels were observed at 52 weeks in the semaglutide than in the empagliflozin group (estimated treatment ratio: 0.74, 95\%CI: 0.65, 0.84, p < 0.0001).\textsuperscript{130} No data exist on lixisenatide, IL-6 and ferritin.

1.6. Sodium Glucose Co-Transporter-2 inhibitors (SGLT2i)

SGLT2i inhibit the renal reabsorption of glucose, thus promoting renal glucose excretion and, subsequently, lowering plasma glucose levels.\textsuperscript{111,112} Potential anti-inflammatory effects have been reported for SGLT2i.\textsuperscript{113}

1.6.1. Empagliflozin

Among 50 T2DM patients with CAD, empagliflozin 10 mg/day significantly lowered CRP at 6 months (from 0.11 to 0.07 mg/dL, p = 0.003).\textsuperscript{114} Empagliflozin 10 mg/day for 12 months also notably reduced hsCRP by 54\% (from 1.33 to 0.59 mg/L, p = 0.007) in 51 T2DM patients.\textsuperscript{115} However, in another study with 58 T2DM patients receiving empagliflozin 25 mg/day for 6 weeks, no significant changes in hsCRP levels were found (2.10 ± 1.72 vs 1.99 ± 1.19 mg/L, baseline vs 6 weeks, respectively).\textsuperscript{116}

Interestingly, empagliflozin was reported to decrease markers of oxidative stress and inflammation (including IL-6) in the lungs of mice, thus suggesting a role in preventing pulmonary fibrosis.\textsuperscript{117} as well as in rat cardiomyoblasts (including reduction of IL-6 expression), thus potenti ally minimizing infarct size.\textsuperscript{118} Similarly, in diabetic rats empagliflozin exhibited anti-oxidant and anti-inflammatory effects in the kidneys; urinary IL-6 levels were also lowered.\textsuperscript{119} Overall, experimental data strongly support a protective role of empagliflozin against cardiac and renal inflammation.\textsuperscript{120,121} However, clinical evidence is lacking. There is one study reporting that empagliflozin significantly reduced circulating IL-6 levels in 32 men T2DM patients; this IL-6-lowering effect of empagliflozin was greater than that of canagliflozin.\textsuperscript{122}

In a large-scale proteomics study, empagliflozin 25 mg/day led to significant decreases in circulating ferritin levels after 4 weeks of treatment.\textsuperscript{123} Furthermore, a sub-study of the EMPA-HEART CardioLink-6 randomized clinical trial, involving 82 T2DM patients with CAD, showed that 6 months of empagliflozin treatment (10 mg/day) was associated with a significant reduction in ferritin levels (mean difference = −21.83 μg/L, 95\%CI: −37.96, −5.7; p = 0.008).\textsuperscript{124}

1.6.2. Dapagliflozin

In animal studies, dapagliflozin was shown to exert anti-oxidant and anti-inflammatory actions in the kidney, liver and lungs.\textsuperscript{125,126} There is also data supporting a CRP-lowering effect of dapagliflozin in humans.\textsuperscript{127} In this context, dapagliflozin 10 mg/day combined with metformin significantly lowered CRP (from 6.2 ± 1.1 to 3.1 ± 0.7 mg/L, p < 0.05) in 59 T2DM patients at 12 weeks\textsuperscript{128} as did dapagliflozin 5 mg/day after 12 weeks (from 2410 ± 2814 to 1607 ± 1960 ng/mL, p < 0.01) in 27 T2DM patients.\textsuperscript{129} In contrast, among 11 T2DM patients with non-alcoholic steatohepatitis, treatment with dapagliflozin 5 mg/day for 24 weeks led to a non-significant reduction in hsCRP.\textsuperscript{129} Furthermore, another study reported a significant increase in median hsCRP levels in 36 T2DM patients treated with dapagliflozin (10 mg/day) for 12 weeks (from 1.93 to 6.03 mg/L, p = 0.009).\textsuperscript{130}

In a randomized, placebo-controlled study (n = 32 T2DM patients), 8 weeks of dapagliflozin (10 mg/day) therapy led to a significant placebo-corrected reduction in IL-6 levels (by −1.87 pg/mL, p < 0.05).\textsuperscript{131} A post-hoc analysis of another randomized, double-blind, placebo-controlled trial involving 33 T2DM patients, found that urinary IL-6 excretion was significantly decreased by 23.5\% (p = 0.04).\textsuperscript{132}

With regard to ferritin, there are studies reporting that dapagliflozin 5 mg/day significantly decreased ferritin levels in T2DM patients with either NASH or non-alcoholic fatty liver disease (NAFLD).\textsuperscript{129,133} Similarly, ferritin was significantly lowered after 12 weeks of dapagliflozin (10 mg/day) therapy in 26 obese T2DM patients.\textsuperscript{134}

1.6.3. Canagliflozin

Among 100 T2DM patients treated with canagliflozin 300 mg/day for 52 weeks, there was a non-significant trend for a decrease in serum CRP levels.\textsuperscript{135} Furthermore, no change was observed in serum CRP after 12 weeks of canagliflozin 100 mg/day therapy in 12 T2DM patients.\textsuperscript{136} In contrast, hsCRP was significantly reduced from baseline at 3, 6 and 12 months of treatment (from 3.09 ± 0.07 to 0.20 ± 0.05, 0.20 ± 0.04 and 0.21 ± 0.04 ng/mL, respectively, p < 0.05) in 35 T2DM patients with chronic heart failure treated with canagliflozin 100 mg/day.\textsuperscript{137}

A proteomic model found that canagliflozin 300 mg/day significantly lowered plasma IL-6 concentrations (by 26.6\%, p = 0.010).\textsuperscript{138} Similar results were reported in animal studies.\textsuperscript{139,140} However, in human studies no significant changes in IL-6 levels have been found following treatment with canagliflozin (100 mg/day, 24 weeks).\textsuperscript{122,141} In contrast, canagliflozin 300 mg/day for 52 weeks was shown to significantly lower serum IL-6 (by 22\%) in 100 T2DM patients.\textsuperscript{135}

In a small study (9 T2DM patients), canagliflozin 100 mg/day for 12 weeks led to a significant decrease in median ferritin levels (from 72 to 55 ng/mL, p = 0.003).\textsuperscript{142} Furthermore, serum ferritin concentrations were significantly and progressively lowered from baseline to 3 and 6 months (from 184.9 to 143.8 and 117.3 ng/mL, respectively, p < 0.05) in 35 canagliflozin (100 mg/day)-treated NAFLD patients.\textsuperscript{143} Similar results were also reported in T2DM patients with biopsy-proven NASH.\textsuperscript{144} Of note, SGLT2i have been suggested for NAFLD/NASH treatment\textsuperscript{145,147} as is the case for pioglitazone and GLP-1 RAs.\textsuperscript{148,149}

Overall, diabetes has been closely linked to inflammation.\textsuperscript{150} Furthermore, HbA\textsubscript{1c} has been positively related to hsCRP, IL-6 and ferritin levels;\textsuperscript{151–155} thus supporting also a role for euglycemia in reducing chronic inflammation in patients with diabetes. Apart from antidiabetic drugs, a healthy lifestyle (including diet, exercise and no smoking) can contribute to glucose and inflammation control.\textsuperscript{156,157} Interestingly, HbA\textsubscript{1c} level was positively associated with inflammation and hypercoagulability, as well as negatively associated with SaO\textsubscript{2} in COVID-19 infected patients,\textsuperscript{158} thus further highlighting the importance of achieving glucose control in the COVID-19 era.

1.7. Limitations of current evidence

Despite the multitude of reports, the data here analyzed (summarized in Table 1 for the human studies) fall short of providing good evidence for a clinically significant anti-inflammatory effect of the most common antidiabetic classes of medication for several reasons. Firstly, studies were frequently small in size or detecting small differences. Secondly, many studies involved patients of Asian origin, without appropriate control for other ethnicities. Thirdly, studies of similar design yielded contrasting results for one or the other biomarker, or inconsistent findings across biomarkers. Finally, and perhaps more importantly, most studies did not control, or were not equipoised, for the anti-hyperglycemic effect, so that a bona fide pharmacologic effect of a given drug cannot be distinguished from a non-specific effect of improved glycaemia.
2. Conclusions

With all these limitations, perhaps the most suggestive data are those on ferritin for the SGLT2 inhibitors, which may be related to enhanced erythropoiesis rather than tissues inflammation. In any event, large, multietnic, equipoised trials would be required to determine whether certain antidiabetic drugs exert inherent anti-inflammatory properties above and beyond their antihyperglycemic efficacy; the latter remains decidedly useful in COVID-19 disease.

Declaration of competing interest

NK has given talks, attended conferences and participated in trials sponsored by Astra Zeneca, Bausch Health, Boehringer Ingelheim, Elpen, Mylan, Novo Nordisk, Sanofi and Servier. EF has received research support by Boehringer Ingelheim/Lilly&Co. AstraZeneca and Janssen and speaker’s honoraria by Boehringer Ingelheim/Lilly&Co., Sanofi and AstraZeneca.

References

1. Saghaiezadeh A, Rezaei N. Immune-epidemiological parameters of the novel coronavirus – a perspective. Expert Rev Clin Immunol 2020;1-6.
2. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020 Apr;3. [Epub ahead of print].
3. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020 Apr;10. [Epub ahead of print].
4. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J et al. Clinical and biochemical indices from 2019-nCoV infected patients linked to viral loads and lung injury. Sci Rep 2020;10:1-11.
5. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical Predictors of Mortality Due to COVID-19 Based on an Analysis of Data of 150 Patients from Wuhan. Intensive Care Med. China. 2020 Mar 3. [Epub ahead of print].
6. Hussain A, Bhowmik B, Cristina da Vale Moreira N. COVID-19 and Diabetes: Knowledge in Progress. Diabetes Res Clin Pract. 2020 Apr 9 [Epub ahead of print].
7. Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis 2020;30:1236-48.
8. Kumar A, Arora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis Diabetes Metab Syndr 2020;14:315-45.
9. Lontchi-Yimagou E, Soengsri E, Matsa TE, Kengne AP. Diabetes mellitus and inflammation. Curr Diab Rep 2013;13:435-44.
10. Natali A, Toschi E, Baldiweg S, Ciociaro D, Favilla S, Saccà L, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 2006;55:1133-46.
11. Pradhan AD, Mansoor JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
12. Elinman H, Abdulla AM, Taha JM. Inflammatory markers and control of type 2 diabetes mellitus. Diabetes Metab Syndr 2019;13:1009-14.
13. King DE, Mainous AG. 3rd, Buchanan TA, Pearson WS. C-reactive protein and glycomic control in adults with diabetes. Diabetes Care 2003;26:1535-9.
14. He Q, Dong M, Pan Q, Wang X, Guo L. Correlation between changes in inflammatory cytokines and the combination of hypertension in patients with type 2 diabetes mellitus. Minerva Endocrinol 2019;44:252-8.
15. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetesologia 2017;60:1577-85.
16. Madluraju A, Qiu Y, Perry BJ, Rahimi Y, Zhang XM, Zhang D et al. Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med 2018;24:1384-94.
17. Saisho Y. Metformin and inflammation: its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets 2015;15:196-205.
18. Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beal C et al. Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res 2016;119:652-65.
19. Akbari DL. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetes with metabolic syndrome. Endocrine 2003;20:215-8.
20. Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract 2011;95:56-62.
21. Hafler S, Temprosa M, Cran dall J, Fowler S, Goldberg R, Horton E et al. Barrett-Connor E: diabetes prevention program research group. Intensive lifestyle intervention in metformin or on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2003;54:1566-72.
22. Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007;66:282-9.
23. Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of initiating insulin and glycerol control in inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA 2009;302:1186-94.
24. Custodero C, Mankowski RT, Lee SA, Chen Z, Wu S, Manini TM et al. Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: a systematic review and meta-analysis. Ageing Res Rev 2018;46:42-59.
25. Wang J, Zhu L, Hu K, Tang Y, Zeng X, Liu J et al. Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis: a PRISMA-compliant article. Medicine (Baltimore) 2017;96:e8183.
26. Di Fusco D, Dinello V, Monteleone I, Laudisi F, Mara di Fusco I, Franzè E et al. Metformin inhibits inflammatory signals in the gut by controlling AMPK and p38 MAP kinase activation. Clin Sci (Lond) 2018;132:1155-68.
27. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006;26:611-7.
28. Chen W, Liu X, Ye S. Effects of metformin on blood and urine pro-inflammatory mediators in patients with type 2 diabetes. J Inflamm (Lond). 2016;13:34.
29. Mo D, Liu S, Ma H, Tian H, Yu H, Zhang X et al. Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a randomized one-year clinical study. Drug Des Devel Ther 2019;13:2759-76.
30. Lebovitz HE. Farnesoid X receptor agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag 2008;4:297-304.
31. Upadhyay J, Polyzos SA, Perakakis N, Thakkar B, Paschou SA, Katsiki N et al. Pharmacotherapy of type 2 diabetes: an update. Metabolism 2018;78:13-42.
32. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006;26:611-7.
33. Chen W, Liu X, Ye S. Effects of metformin on blood and urine pro-inflammatory mediators in patients with type 2 diabetes. J Inflamm (Lond). 2016;13:34.
34. Mo D, Liu S, Ma H, Tian H, Yu H, Zhang X et al. Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a randomized one-year clinical study. Drug Des Devel Ther 2019;13:2759-76.
35. Lebovitz HE. Farnesoid X receptor agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag 2008;4:297-304.
36. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006;26:611-7.

Table 1

| Antidiabetic Drugs | C-reactive protein | Interleukin-6 | Ferritin |
|--------------------|------------------|--------------|---------|
| Metformin          | No data          | No data      | No data |
| Pioglitazone       | No data          | No data      | No data |
| Sitagliptin        | No data          | No data      | No data |
| Linagliptin        | No data          | No data      | No data |
| Vildagliptin       | No data          | No data      | No data |
| Alogliptin         | No data          | No data      | No data |
| Saxagliptin        | No data          | No data      | No data |
| Lisinamide         | No data          | No data      | No data |
| Semaglutide        | No data          | No data      | No data |
| Empagliflozin      | No data          | No data      | No data |
| Dapagliflozin      | No data          | No data      | No data |
| Canagliflozin      | No data          | No data      | No data |
37. Chen R, Yan J, Liu P, Wang Z. Effects of thiazolidinedione therapy on inflammatory markers of type 2 diabetes: a meta-analysis of randomized controlled trials. PLoS One 2015;10, e0137203.

38. Shao S, Xu Q, Yu X, Pan R, Chen Y. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacol Ther 2020;209:107503.

39. Liu X, Men P, Wang B, Cai G, Zhao Z. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis. LipoMet 2013;18:144.

40. Sun Y, Yan D, Hao Z, Cui L, Li G. Effects of dapagliflozin and sitagliptin on insulin resistant body fat distribution in newly diagnosed type 2 diabetic patients. Med Sci Monit 2020;26, e921981.

41. Sato-Shakura N, Sato T, Wada H, Tochiya M, Ieguchi A, Nakagawachi R, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism 2013;62:347-51.

42. Mahdissi A, Ghimni H, Vora M, Green K, AbuShawareh S, Chaudhuri A, et al. Sitagliptin and metformin for the treatment of neuropathy and oxidative stress. J Clin Pharmacol 2013;53:1337-41.

43. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effects of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month open-label, randomised controlled trial. Cardiovasc Diabetol 2014;13:110.

44. Wang Z, Yan J, Liu P, Chen R. Effects of thiazolidinedione therapy on inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism 2014;63:1141-8.

45. Derosa G, Maffioli P, Salvadore SA, Ferrari I, Ragonese PD, Querci F, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-95.

46. Derosa G, Maffioli P, Salvadore SA, Ferrari I, Ragonese PD, Querci F, et al. Effects of a combination of sitagliptin or metformin vs metformin monotherapy on glycemic control, C-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 2012;98:51-60.

47. Derosa G, Maffioli P, Salvadore SA, Ferrari I, Ragonese PD, Querci F, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-95.

48. Tsurutani Y, Omura M, Matsuzawa Y, Saito J, Higa M, Taniyama M, Nishikawa T; dipeptidyl peptidase-4 inhibitor study group. Cardiovascular effects of dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes. J Clin Endocrinol Metab 2012;97:3337-41.

49. Tsurutani Y, Omura M, Matsuzawa Y, Saito J, Higa M, Taniyama M, Nishikawa T; single-Y investigation group. Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, C-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who Are Treatment Naïve or Poorly Controlled. J Therapeutic Agents: A Multinational, Prospective Observational, Uncontrolled Study. Curr Ther Res Clin Exp 2017;84:26-31.

50. Nakamura T, Iwasaka Y, Miyoshi Y, Nohara R, Ishimura T, Miyazaki S. Sitagliptin Improves Sympathetic Activity and Cardiomyocyte Function in Diabetic Mice. Scientific, cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up. Cardiovasc Diabetol 2016;15:54.

51. Noguera KC, Furtado M, Fukui RT, Correa MR, Dos Santos RF, Andrade JL, Rossi da Silva ME. Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor - a pilot study. Diabetol Metab Syndr 2014;6(1):103.

52. Nakamura K, Ke H, Kihara H, Shinada K, Fukuda S, Watanabe K, et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol 2014;13:110.

53. Liu SC, Chen KL, Wang CH, Chen WC, Leung CH. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin: a randomized, double-blind, controlled, 26-week trial (RELEASE). Diabetes Obes Metab 2017;19:1147-54.

54. Liu X, Mei T, Chen W, Ye S. Comparison of antidiabetic treatments during the treatment of atherothrombosis in T2DM patients. Mediators Inflamm 2017;2017:5032708.

55. Zionski S, Barnard M, Prescott E, Jones R, Shah FT, Tzouli P. Effectiveness and safety of sitagliptin in patients with type 2 diabetes mellitus: a case series. Med J 2015 Hematol Infect Dis 2017;9, e200704.

56. Nakamura Y, Tsuji M, Hasegawa H, Kimura K, Fujita K, Inoue M, et al. Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes. Hemodial Int 2014;18:433-43.

57. Terawaki Y, Nomiyama T, Takahashi H, Uchida Y, Yamanaka K, et al. The effect of DPP-4 inhibitors on C-reactive protein, adipocyte function and insulin resistance in type 2 diabetic patients. J Endocrinol Invest 2013;36:180-8.

58. Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osono T, Shiroma K, Tosa M, Unanuma Y, Yamanaka H, Yamakita M, Tomokuno T, Komiyama H, Kameda H, Cho KY, Nakamura A, et al. Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuation evaluated by long-term self-monitoring of blood glucose. Endocr J 2017;64:417-24.

59. Rizzo MR, Barbieri M, Marfella R, Paolasso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor. J Clin Endocrinol Metab 2018;103:149-58.

60. Yuan J, Takeshita K, Ban M, Chen Y, Liu H, Uchida Y, Yamanaka K, et al. Dipeptidyl peptide-4 inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model. Psychoneuroendocrinology 2016;73:186-95.

61. Th, Schuyler CA, Li Y, Lopez-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011;58:157-66.

62. Guo Q, Zhang S, Huang J, Liu K. Alogliptin inhibits IL-1β-induced inflammatory response in fibroblast-like synoviocytes. Int Immunopharmacol 2020;83:106372.

63. Birnbaum Y, Bajaj M, Qian J, Ye Y. Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome. BMJ Open Diabetes Res Care 2016;4, e000227.

64. Scirica BM, Braunwald E, Ray C, Cadena MV, Morrison DA, Jelusich F, et al. NAVIGATE-TIMI 53: interim analysis and final results of a randomized trial of vildagliptin in patients after acute coronary syndromes. Am Heart J 2013;165:995-1003.

65. Derosa G, Maffioli P, Salvadore SA, Ferrari I, Ragonese PD, Querci F, et al. Effects of a combination of sitagliptin or metformin vs metformin monotherapy on glycemic control, C- cell function and insulin resistance in type 2 diabetic patients. J Endocrinol Invest 2017;40:1397-404.

66. Mei J, Sun J, Wu J, Zheng X. Liraglutide suppresses TNF-α-induced degradation of extracellular matrix in human chondrocytes. A therapeutic implication in osteoarthritis. Am J Transl Res 2019;11:4800-8.

67. Choe EY, Cho Y, Choi Y, Yun Y, Wang HJ, Kwon O, et al. The effect of DPP-4 inhibitors on C-reactive protein, adipocyte function and insulin resistance in type 2 diabetic patients. J Endocrinol Invest 2014;37:186-90.
104. Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, et al. Exenatide. Diabetes Care 2012;35:1404-12.

103. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Sodium-glucose cotransporter 2 inhibitors and in diabetes mellitus: effect of Liraglutide. Diabetes Care 2019;42:2272-81.

101. Mafong DD, Henry RR. Exenatide as a treatment for diabetes and obesity: implications of a randomized controlled trial. Atherosclerosis 2009;203:288-60.

102. Simone P, Liani R, Tripaldi R, Di Castelnuovo A, Guagnano MT, Tartaro A, Bonadonna RC, Federico V, Cipollone F, Consoli A, Santilli F. Thrombomodulate-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss. Nutrients. 2018;10:12.

100. Forst T, Michelson G, Ratter F, Weber MM, Anders S, Mitry M, et al. Addition of exenatide to metformin in patients with type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med 2012;29:1115-1118.

99. Courrêges JP, Vinbakk T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, et al. Beneficial effects of once-daily lixisenatide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabetes Metab 2008:25:1129-31.

98. Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, et al. Effects of once-daily lixisenatide against in diabetic patients with type 2 diabetes accompanied by incipient nephropathy. Exp Ther Med 2012;13:143-8.

97. Liu W, Yu J, Tian T, Miao J, Shang W. Meta-analysis of the effect of the SGLT-2 inhibitor dapagliflozin on liver enzymes and markers of inflammation in subjects with type 2 diabetes mellitus. J Diabetes. 2019;11:1130-11358.

96. Katsiki N, Mikhailidis DP, Theodorakis MJ. Sodium-glucose cotransporter 2 inhibitors: their role in cardiometabolic risk management. Curr Pharm Des 2018;24:256-62.

95. Liu W, Yu J, Tian T, Miao J, Shang W. Meta-analysis of the effect of the SGLT-2 inhibitor empagliflozin on liver enzymes and markers of inflammation in patients with type 2 diabetes mellitus. J Diabetes. 2018;10(12).

94. Fernandez-Herrera A, Feijoó-Bandín S. Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, et al. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol 2019;170:11307-15.

93. Yaribeygi H, Butler AE, Atkin SL, Katsiki N, Sahebkar A. Sodium-glucose cotransporter 2 inhibitors and insulin resistance. Diabetes Care 2010;33:1734-7.
139. Ali BH, Al Salam S, Al Suleimani Y, Al Zaabi M, Abdelrahman AM, Ashique M, et al. Effects of the SGLT-2 inhibitor canagliflozin on adenine-induced chronic kidney disease in rats. Cell Physiol Biochem 2019;52:27-39.

140. Abdelrahman AM, Al Suleimani Y, Shalaby A, Ashique M, Manoj P, Nemmar A, et al. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice. Naunyn Schmiedebers Arch Pharmacol 2019;392:45-53.

141. Koike Y, Shirabe SI, Maeda H, Yoshimoto A, Arai K, Kumakura A, et al. Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2019;149:140-6.

142. Maruyama T, Takashima H, Oguma H, Nakamura Y, Ohno M, Utsunomiya K, et al. Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease. Diabetes Technol Ther 2019;21:713-20.

143. Itani T, Ishihara T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. Obes Sci Pract 2018;4:477-82.

144. Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, et al. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. Diabetes Metab Syndr Obes 2018;11:833-43.

145. Athyros VG, Polyzos SA, Kountouras J, et al. Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block. Curr Vasc Pharmacol 2020;18:172-81.

146. Katsiki N, Perakakis N, Mantzoros C. Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: ex quo et quo vadimus? Metabolism 2019;98:iii-ix.

147. Katsiki N, Athyros VG, Mikhailidis DP. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: effects of statins and antidiabetic drugs. J Diabetes Complications 2017;31:521-2.

148. Ranjbar G, Mikhailidis DP, Sahbekar A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box! Metabolism 2019;101:154001.

149. Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Gouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tsapenidis AD, Tsoufis K, Tziomalos K, Tzotzas T, Vlassiadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 2017;71:17-32.

150. Donath MY, Meier DT, Böni-Schuepbacher M. Inflammation in the pathophysiology and therapy of cardiometabolic disease. Endocr Rev 2019;40:1080-91.

151. Bahceci M, Tuzcu A, Ogun C, Canoruc N, Ilitmir K, Aslan C. Is serum C-reactive protein concentration correlated with HbA1c and insulin resistance in type 2 diabetic men with or without coronary heart disease? J Endocrinol Invest 2005;28:145-50.

152. Ahmadi-Abbasi S, Kaprote S, Luben RN, Wareham NJ, Khaw KT. Longitudinal association of C-reactive protein and Haemoglobin A1c over 13 years: the European Prospective Investigation into Cancer—Norfolk study. Cardiovasc Diabetol 2015;14:61.

153. Zhao Y, Tang Z, Yu J. Serum ferritin, diabetes, diabetes control, and insulin resistance. Acta Diabetol 2014;51:991-8.

154. Batchuluun B, Matsumata T, Batchuluun B, et al. Serum ferritin level is higher in poorly controlled patients with type 2 diabetes and people without diabetes, aged over 55 years. Diabet Med 2014;31:419-24.

155. Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, Al-Abri S, Al-Lawati J, Al-Maskari M. Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol 2013;2013:976810.

156. Mihalane AM, Vinoy S, Russell WR, et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. Br J Nutr 2015;114:999-1012.

157. Pedersen BK. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease. Eur J Clin Invest 2017;47:600-11.

158. Wang Z, Du Z, Zhu F. Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res Clin Pract 2020;164:108214.